论文部分内容阅读
目的:研究钙拮抗剂地尔硫唑是否逆转慢性充德性心力衰竭(CHF)患者淋巴细胞膜β肾上腺素受体(β-AR)的下调.方法:同位素放射配基法测定地尔硫唑治疗前后CHF患者淋巴细胞β-AR密度,Fura 2-AM荧光指示法测定血小板胞内[Ca~(2+)]_i,放射免疫法测定血浆去甲肾上腺素(NE)浓度的变化.结果:CHF患者淋巴细胞β-AR密度低于对照组.血小板[Ca~(2+)]_i及血浆NE水平均高于对照组.地尔硫唑降低血小板[Ca~(2+)]_i,升高淋巴细胞β-AR密度.治疗前后血浆NE水平无显著变化.无论治疗前后,血小板[Ca~(2+)]_i与淋巴细胞β-AR密度均呈负相关.结论:地尔硫唑能够部分逆转心衰患者β-AR的下调,这种作用与血浆NE水平变化无关,而可能与降低细胞内[Ca~(2+)]_i有关.
AIM: To investigate whether diltiazem, a calcium antagonist, reverses the downregulation of β-adrenergic receptor (β-AR) in patients with chronic heart failure with congestive heart failure.Methods: Determination of diltiazem treatment with isotope radioligand The concentration of β-AR in lymphocytes of CHF patients before and after CHF, the intracellular Ca ~ (2 +) _ i in the platelets by Fura 2-AM fluorescence assay, and the plasma norepinephrine (NE) concentration were measured by radioimmunoassay.Results: The density of β-AR of lymphocyte in patients was lower than that in control group, and the levels of [Ca ~ (2 +)] i and plasma NE were higher than those in control group.Dilirubin reduced the [Ca ~ (2 +)] _i, There was no significant difference of plasma NE level before and after treatment in both groups (P <0.05) .No significant difference was found in plasma NE level between before and after treatment.Conclusion: Diltiazem could partly The reversal of heart failure in patients with β-AR down regulation, this effect has nothing to do with changes in plasma NE levels, and may be related to the reduction of intracellular [Ca ~ (2 +)] _i.